Ionis Pharmaceuticals won wider U.S. FDA approval for Tryngolza (olezarsen), moving the therapy beyond its rare form of familial chylomicronemia syndrome and into severe hypertriglyceridemia. The expanded indication follows earlier clinical efficacy results and adds Tryngolza to a more prevalent cardiometabolic category, positioning Ionis to commercialize in a larger patient pool. The approval also gives the company a new scale opportunity after decades of partnership-led development for some assets. Clinically, the label expansion affects how clinicians view targeted RNA-based therapeutics for triglyceride-driven pancreatitis risk and intensifies competition in lipid-lowering specialty care.